129042-57-5Relevant articles and documents
-
Rodionow,Kurtew
, (1953)
-
Ruthenium-catalyzed asymmetric epoxidation of olefins using H 2O2, part I: Synthesis of new chiral N,N,N,-tridentate pybox and pyboxazine ligands and their ruthenium complexes
Tse, Man Kin,Bhor, Santosh,Klawonn, Markus,Anilkumar, Gopinathan,Jiao, Haijun,Doebler, Christian,Spannenberg, Anke,Magerlein, Wolfgang,Hugl, Herbert,Beller, Matthias
, p. 1855 - 1874 (2008/02/02)
The synthesis of chiral tridentate N,N,N-pyridine-2.6-bisoxazolines 3 (pyhox ligands) and N,N,N-pyridine-2.6-bisoxazines 4 (pyboxazine ligands) is described in detail. These novel ligands constitute a useful tool-box for the application in asymmetric catalysis. Compounds 3 and 4 are conveniently prepared by cyclization of enantiomerically pure α- or β-amino al cohols with dimethyl pyridine-2,6-dicarboximidate. The corresponding ruthenium complexes are efficient asymmetric epoxidation catalysts and have been prepared in good yield and fully char acterized by spectroscopic means. Four of these ruthenium complexes have been characterized by X-ray crystallography. For the first time the molecular structure of a pyboxazine complex (2,6-bis-[(4S)-4-phenyl-5,6- dihydro-4H-[1,3]oxazinyl]pyridine)(pyridine-2,6-dicarboxylate)ruthenium (S)-2aa, is presented.
Novel malonamide derivatives as αvβ3 antagonists. Syntheses and evaluation of 3-(3-indolin-1-yl-3-oxopropanoyl)aminopropanoic acids on vitronectin interaction with αvβ3
Nagashima,Akamatsu,Kawaminami,Kawazoe,Ogami,Matsumoto,Okada,Suzuki,Tsukamoto
, p. 1420 - 1432 (2007/10/03)
In attempt to find novel integrin of αvβ3 antagonists, we selected SC65811 and its guanidine analogue (1) as lead compounds. Modification of the glycine part of SC65811 led to a new series of malonamide derivatives that exhibited αvβ3 inhibitory activity. Among them, (R,S)-3-{3-[6-(3-benzylureido)indolin-1-yl]-3-oxopropanoylamino}-3- (pyridin-3-yl)propanoic acid (43a) showed not only potent activity with an IC50 value of 3.0 nM but also good selectivity for αvβ3 relative to αIIbβ3, α5β1, and αvβ5 with IC50 values of 19000, 11000, and 14 nM, respectively. Furthermore, optimization of 43a led to the most potent αvβ3 antagonist, (R,S)-3-(3-{6-[(4,5-dihydro-1H-imidazol-2-yl)aminoindolin-1-yl}- 3-oxopropanoylamino)-3-(quinolin-3-yl)propanoic acid (431) with an IC50 value of 0.42 nM. The synthesis and the structure-activity relationships of these malonamide derivatives are presented.